CClinicalTrials.gg
RecruitingNCT05902936Updated Jun 15, 2023

Evaluation of Nano Bioactive Glass Combined With i-PRF Scaffold in Vital Pulp Treatments

An interventional study of Pulpotomy for mature permanent mandibular molars in Pulpitis - Irreversible and Apical Periodontitis, sponsored by Cairo University. Recruiting at 1 site in Egypt. Open to participants aged 10 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-06-15.

Sponsored by Cairo University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Mar 2024, 2 years 7 months ago, but the record still lists the study as recruiting.
  • Started Mar 2023; still recruiting 3 years 7 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
10 Years to 50 Years
Sex
All
01

Study summary

With consideration of the previous studies regarding the properties of i-PRF, it will be used in combination with another bioactive material: (Nano-BAG) versus using of i-PRF only as a pulpotomy material with using a premixed bioceramic putty as a coronal sealing material in both cases, to evaluate if there is a difference in the success rate of pulpotomy in case of using Nano-BAG in combination with i-PRF

So, in this study the investigators will use Nano-BAG in combination with i-PRF as a material for pulpotomy in cases of mature permanent mandibular molars and compare its outcomes with using i-PRF only and in both cases pulpotomy material will be covered with a layer of premixed bioceramic putty for coronal sealing.

Read the detailed description

The aim of this study is to evaluate the outcome of i-PRF mixed with Nano-bioactive Glass powder and i-PRF alone covered with a layer of premixed bioceramic putty when used as a material for pulpotomy in terms of relieving pain and maintaining the radicular pulp vitality and inducing dentin bridge formation in mature permanent mandibular molars.

Research Question:

Will i-PRF mixed with Nano-BAG and covered with premixed bioceramic putty gives similar results in relieving pain , conservation of the radicular pulp vitality and dentin bridge formation compared with i-PRF alone covered with premixed bioceramic putty when using it as a material for pulpotomy in mature permanent mandibular molars?

Interventions:

A- Intervention for each group

a- General operative procedures

  • Eligible patients will be randomized in equal proportions between the two groups.

Patients of the two groups will be subjected to:

  • Diagnosis using diagnostic chart (appendix A) and selected according to inclusion and exclusion criteria
  • Comprehensive clinical examination and understanding of patients' chief complaint and needs.
  • Standard preoperative digital x-ray for all patients.

B- Intra operative procedures: (For both groups) Before anesthesia, surfaces of the teeth will be cleaned to be free of debris, calculus and plaque. Teeth will first be dried and isolated with cotton rolls and a tooth paste will be applied on the buccal face of the crown as an interface media. An electric pulp tester (EPT) probe will be placed on the sound coronal third of the labial surface and the responses will be recorded before starting the treatment. The contra lateral tooth will be tested first for comparison and then the subjected tooth will be checked.

The procedures will be performed under local anesthesia with Lidocaine 2% and adrenaline 1/100,000. Teeth will be isolated with rubber dam.

All carious tissue and old restoration (if present) will be removed with a diamond stone size 1 in a high speed hand piece with coolant , once the pulp is exposed the diamond stone will be changed and another sterile one will be used for complete deroofing of the pulp chamber. Then a sharp sterile excavator will be used for amputation of the coronal pulp tissue to the level of the root canal orifices.

Haemostasis will be achieved by pressing sterile cotton pellets soaked with sterile saline and damped into the cavity for 5-10 minutes over the pulp stumps (If haemostasis cannot be achieved after 10 mins, the tooth should undergo root canal treatment)

Care should be taken to minimize the time elapsed between coronal pulp amputation and placement of pulpotomy agent. The teeth will be then divided into two groups depending on the pulpotomy agents. I-PRF will be prepared according to Choukroun's technique by drawing a whole blood sample from the median cubital vein into a 10 ml plain test tubes (Non-citrated) to prevent blood coagulation then it will be centrifuged immediately using a table top centrifuge at 700 rpm for 3 mins The whole blood sample that will be obtained consists of three layers: the top most layer of acellular platelet poor plasma, the middle layer of platelet rich fibrin, and the bottom most layer of red blood corpuscles. The upper yellow fluid liquid (i-PRF) will be collected as close as possible to the layer of red blood cell.

Group A (the control group) :

After control of bleeding in teeth allocated to the control group i-PRF is to be injected first. The i-PRF will be injected into the root canal to a level 3 mm below the cementoenamel junction (CEJ).

Group B (In the intervention group):

After control of bleeding in teeth allocated to the intervention group, i-PRF is to be mixed with Nano-BAG powder to a putty consistency and injected into the root canal to a level 3 mm below the cementoenamel junction (CEJ), then a layer of premixed bioceramic putty is to be added for coronal sealing.

Coronal Sealing:

After a period of 10-15-minutes is allowed for coagulation, the coronal sealing material will be applied. The premixed bioceramic putty is dispensed on a sterile glass slab using a flat sided sterile plastic instrument. The material is applied over the coagulated scaffold in both groups using a dedicated carrier (MAP one) The material is adapted over the scaffold using light pressure adaptation with a sterile micro-brush of suitable size.

Final restoration:

A thin layer of resin-modified glass ionomer cement (RMGIC) to be applied directly over the coronal seal. Composite Resin material is to be used as a final restoration.

02

Conditions studied

  • Pulpitis - Irreversible
  • Apical Periodontitis
03

In context

Periodontitis

1,635 studies on the registry are indexed under Periodontitis; 327 are open to participants now.

This study's planned enrollment of 30 is below the median of 45 across 1,191 interventional studies indexed under Periodontitis.

Browse Periodontitis studies →

Lead sponsor

Cairo University is the lead sponsor of 4,780 studies on the registry; 1,427 are open to participants now.

Of its 36 completed or terminated interventional studies of FDA-regulated products, 5 (14%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
10 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

    • Patients suffering from symptomatic irreversible pulpitis.

      • Tooth should give positive response to cold test
      • Heamostatis should be achieved after complete pulpotomy
      • Diagnosis is irreversible pulpitis with/without apical periodontitis
      • The tooth is restorable and free from advanced periodontal disease
      • Tooth is free from cracks or splits
      • Patients should be free from any systemic disease that may affect normal healing and predictable outcomes.
      • Patients who will agree to the consent and will commit to follow-up period.
      • Patients with mature root (closed apices)
      • Teeth with no periapical lesion, resorption or widening.
      • Soft tissues around the tooth are normal with no swelling or sinus tract
      • Mandibular posterior teeth only will be involved.

Exclusion criteria

Exclusion Criteria:

    • Patients with immature root apices.

      • Patients with any systemic disease that may affect normal healing.
      • Patients with periapical lesions or infections.
      • If heamostasis couldn't be achieved within 5-10 minutes
      • Pregnant females.
      • Patients who could/would not participate in a 6 months follow-up.
      • Patients with fistula or swelling
      • Patients with necrotic pulp.
      • Patients with old age.
      • Badly destructed teeth
      • Teeth that are non-restorable
      • Teeth that require post and core build up
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Control group

    After control of bleeding in teeth allocated to the control group i-PRF is to be injected first. The i-PRF will be injected into the root canal to a level 3 mm below the cementoenamel junction (CEJ) then a layer of premixed bioceramic putty is to be added for coronal sealing.

    Procedure: Pulpotomy for mature permanent mandibular molars

  • Active comparator
    Intervention group

    After control of bleeding in teeth allocated to the intervention group, i-PRF is to be mixed with Nano bioactive glass (Nano-BAG) powder to a putty consistency and injected into the root canal to a level 3 mm below the cementoenamel junction (CEJ), then a layer of premixed bioceramic putty is to be added for coronal sealing.

    Procedure: Pulpotomy for mature permanent mandibular molars

Interventions

  • ProcedurePulpotomy for mature permanent mandibular molars

    Performing pulpotomy for mature teeth that involves removal of the coronal pulp tissue that is diseased or inflammed followed by placement of a biocompatible material with the intent of maintaining the vitality of the remaining radicular pulp tissue.

    Also known as: Vital pulp therapy

06

What researchers measure

Primary outcomes

  1. Pain measurement (change is being assessed)

    Measurement of the change in pain intensity using Visual Analogue Scale from 0 to 10 where higher scores mean higher pain intensity

    Time frame: After 24 hours and up to 7 days for postoperative pain evaluation using Visual Analogue Scale.

Secondary outcomes

  1. Radiographic assesment (change is being assessed)

    Radiographic assesment of dentin bridge formation whether it is present or absent

    Time frame: at 1 month , 3 months and 6 months

  2. Tooth sensibility (change is being assessed)

    Tooth sensibility will be assessed using Thermal (cold) test

    Time frame: at 1 month , 3 months and 6 months

07

Study locations

1 of 1 sites recruiting
  • Faculty of oral and dental medicine - Cairo University
    Cairo, 11511, Egypt
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05902936
Lead sponsor
Cairo University
Responsible party
Peter Nabil Naguib (Principal Investigator, Cairo University) — Principal investigator
First posted
Jun 15, 2023
Start date
Mar 1, 2023
Primary completion
Mar 2024 (estimated)
Completion
Mar 2024 (estimated)
Last update
Jun 15, 2023

Study contacts

Geraldine Ahmed, Professor
Contact
geraldine.ahmed@gmail.com
01226322227

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion